Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
企業コードILMN
会社名Illumina Inc
上場日Jun 28, 2000
設立日2000
最高経営責任者「CEO」Mr. Jacob Thaysen, Ph.D.
従業員数8970
証券種類Ordinary Share
決算期末Jun 28
本社所在地5200 Illumina Way
都市SAN DIEGO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号92122
電話番号18582024500
ウェブサイトhttps://www.illumina.com
企業コードILMN
上場日Jun 28, 2000
設立日2000
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし